Literature DB >> 2176140

Immune responses to fractionated cytomegalovirus (CMV) antigens after HIV infection. Loss of cellular and humoral reactivity to antigens recognized by HIV-, CMV+ individuals.

P J Converse1, T E Fehniger, A Ehrnst, O Strannegård, S Britton.   

Abstract

In order to delineate the molecular pathogenesis of the increased susceptibility to CMV disease in HIV infection, the patterns of antigen responsiveness in HIV-infected and non-infected individuals were investigated. CMV was fractionated by SDS-PAGE and electroblotted onto nitrocellulose. Lymphoproliferative responses of healthy HIV-, CMV+ individuals and HIV+, CMV+ asymptomatic patients to a whole CMV antigen preparation and to 20 fractions of nitrocellulose-bound CMV were then compared. Three fractions of approximate molecular weight of 130-165, 65-75, and 55-65 kD appeared to contain the major T cell stimulating antigens for HIV-, CMV+ individuals. A statistically significant depression of responses to fractions containing antigens in the ranges of 130-165 kD and 55-65 kD but not to whole CMV was seen in HIV+ individuals compared with controls. In healthy controls, the sum of the proliferative responses as measured by 3H-thymidine uptake to these three major fractions was approximately equal to the response to a whole CMV antigen preparation, whereas it was less than half of this response in five out of six HIV+ subjects. When antibody activities to CMV antigens were analysed by immunoblotting of sera from the two subject groups and also sera of ARC and AIDS patients, a selective loss of reactivity was revealed in 10 out of 19 HIV+ subjects to a band of 26-28 kD whereas all 15 HIV-, CMV+ controls recognized this band. Serum IgG and IgM values were both significantly higher in HIV+ individuals than in controls. These findings suggest that specific lesions in the repertoire of immune responsiveness to CMV antigens occur in HIV+ individuals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2176140      PMCID: PMC1535510          DOI: 10.1111/j.1365-2249.1990.tb05490.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  Immunoblot analysis of the humoral immune response in primary cytomegalovirus infection.

Authors:  D Gold; R Ashley; H H Handsfield; M Verdon; L Leach; J Mills; L Drew; L Corey
Journal:  J Infect Dis       Date:  1988-02       Impact factor: 5.226

2.  Immunoaffinity purification of a 72K early antigen of human cytomegalovirus: analysis of humoral and cell-mediated immunity to the purified polypeptide.

Authors:  B Rodgers; L Borysiewicz; J Mundin; S Graham; P Sissons
Journal:  J Gen Virol       Date:  1987-09       Impact factor: 3.891

3.  A simple new method for using antigens separated by polyacrylamide gel electrophoresis to stimulate lymphocytes in vitro after converting bands cut from Western blots into antigen-bearing particles.

Authors:  C Abou-Zeid; E Filley; J Steele; G A Rook
Journal:  J Immunol Methods       Date:  1987-04-02       Impact factor: 2.303

4.  T lymphocytes respond to solid-phase antigen: a novel approach to the molecular analysis of cellular immunity.

Authors:  D B Young; J R Lamb
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

5.  Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection.

Authors:  B Wahren; L Morfeldt-Månsson; G Biberfeld; L Moberg; A Sönnerborg; P Ljungman; A Werner; R Kurth; R Gallo; D Bolognesi
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

6.  Early effects of HIV on CD4 lymphocytes in vivo.

Authors:  J V Giorgi; J L Fahey; D C Smith; L E Hultin; H L Cheng; R T Mitsuyasu; R Detels
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

7.  A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection.

Authors:  S Jonjić; M del Val; G M Keil; M J Reddehase; U H Koszinowski
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

8.  Recombinant HIV structural proteins detect specific cellular immunity in vitro in infected individuals.

Authors:  J W Torseth; P W Berman; T C Merigan
Journal:  AIDS Res Hum Retroviruses       Date:  1988-02       Impact factor: 2.205

9.  Reactivity of cytomegalovirus structural polypeptides with different subclasses of IgG present in human serum.

Authors:  M P Landini; B Baldassarri; G Mirolo; A Ripalti; M La Placa
Journal:  J Infect       Date:  1988-03       Impact factor: 6.072

10.  Decline of anti-p24 antibody precedes antigenaemia as correlate of prognosis in HIV-1 infection.

Authors:  S M Forster; L M Osborne; R Cheingsong-Popov; C Kenny; R Burnell; D J Jeffries; A J Pinching; J R Harris; J N Weber
Journal:  AIDS       Date:  1987-12       Impact factor: 4.177

View more
  13 in total

1.  Immune reactivity to fractionated Leishmania aethiopica antigens during coinfection with human immunodeficiency virus type 1.

Authors:  S C Arya
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

2.  Diagnostic assays in cytomegalovirus retinitis.

Authors:  S Mitchell
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

3.  Pathogenic and protective correlates of T cell proliferation in AIDS. HNRC Group. HIV Neurobehavioral Research Center.

Authors:  R D Schrier; C A Wiley; C Spina; J A McCutchan; I Grant
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

4.  Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected rhesus macaques.

Authors:  A Kaur; M D Daniel; D Hempel; D Lee-Parritz; M S Hirsch; R P Johnson
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Global dysfunction of CD4 T-lymphocyte cytokine expression in simian-human immunodeficiency virus/SIV-infected monkeys is prevented by vaccination.

Authors:  Paul F McKay; Dan H Barouch; Jörn E Schmitz; Ronald S Veazey; Darci A Gorgone; Michelle A Lifton; Kenneth C Williams; Norman L Letvin
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  Hepatitis C virus infection in individuals with or without human immunodeficiency virus type 1 infection.

Authors:  A Sönnerborg; A Abebe; O Strannegård
Journal:  Infection       Date:  1990 Nov-Dec       Impact factor: 3.553

7.  Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group.

Authors:  R D Schrier; W R Freeman; C A Wiley; J A McCutchan
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Antibody responses to synthetic peptides from cytomegalovirus phosphoprotein 150.

Authors:  V A Sundqvist; W Xu; B Wahren
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

9.  Longitudinal study of cytomegalovirus antibodies in individuals infected with the human immunodeficiency virus.

Authors:  R W Flø; G Haukenes; A Nilsen; R Skjaerven; M Forsgren; T E Fehniger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

10.  A longitudinal study of the IgG antibody response to HIV-1 p17 gag protein in HIV-1+ patients with haemophilia: titre and avidity.

Authors:  D Chargelegue; C M O'Toole; B T Colvin
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.